191 related articles for article (PubMed ID: 32194174)
1. Evasion of the accelerated blood clearance phenomenon by polysarcosine coating of liposomes.
Son K; Ueda M; Taguchi K; Maruyama T; Takeoka S; Ito Y
J Control Release; 2020 Jun; 322():209-216. PubMed ID: 32194174
[TBL] [Abstract][Full Text] [Related]
2. Polysarcosine-Coated liposomes attenuating immune response induction and prolonging blood circulation.
Hu M; Taguchi K; Matsumoto K; Kobatake E; Ito Y; Ueda M
J Colloid Interface Sci; 2023 Dec; 651():273-283. PubMed ID: 37542902
[TBL] [Abstract][Full Text] [Related]
3. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration.
Abu Lila AS; Nawata K; Shimizu T; Ishida T; Kiwada H
Int J Pharm; 2013 Nov; 456(1):235-42. PubMed ID: 23928149
[TBL] [Abstract][Full Text] [Related]
4. Evasion of the accelerated blood clearance phenomenon by branched PEG lipid derivative coating of nanoemulsions.
Liu M; Zhao D; Yan N; Li J; Zhang H; Liu M; Tang X; Liu X; Deng Y; Song Y; Zhao X
Int J Pharm; 2022 Jan; 612():121365. PubMed ID: 34896215
[TBL] [Abstract][Full Text] [Related]
5. Hydrophobic blocks of PEG-conjugates play a significant role in the accelerated blood clearance (ABC) phenomenon.
Shiraishi K; Hamano M; Ma H; Kawano K; Maitani Y; Aoshi T; Ishii KJ; Yokoyama M
J Control Release; 2013 Feb; 165(3):183-90. PubMed ID: 23220106
[TBL] [Abstract][Full Text] [Related]
6. Hepatosplenic phagocytic cells indirectly contribute to anti-PEG IgM production in the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes: Appearance of an unexplained mechanism in the ABC phenomenon.
El Sayed MM; Takata H; Shimizu T; Kawaguchi Y; Abu Lila AS; Elsadek NE; Alaaeldin E; Ishima Y; Ando H; Kamal A; Sarhan HA; Ishida T
J Control Release; 2020 Jul; 323():102-109. PubMed ID: 32278827
[TBL] [Abstract][Full Text] [Related]
7. Branched PEG-modification: A new strategy for nanocarriers to evade of the accelerated blood clearance phenomenon and enhance anti-tumor efficacy.
Liu M; Li J; Zhao D; Yan N; Zhang H; Liu M; Tang X; Hu Y; Ding J; Zhang N; Liu X; Deng Y; Song Y; Zhao X
Biomaterials; 2022 Apr; 283():121415. PubMed ID: 35217484
[TBL] [Abstract][Full Text] [Related]
8. Recent progress on polySarcosine as an alternative to PEGylation: Synthesis and biomedical applications.
Kabil MF; Azzazy HME; Nasr M
Int J Pharm; 2024 Mar; 653():123871. PubMed ID: 38301810
[TBL] [Abstract][Full Text] [Related]
9. A Maleimide-Terminally Modified PEGylated Liposome Induced the Accelerated Blood Clearance Independent of the Production of Anti-PEG IgM Antibodies.
Ishima Y; Yamazaki N; Chuang VTG; Shimizu T; Ando H; Ishida T
Biol Pharm Bull; 2022; 45(10):1518-1524. PubMed ID: 36184510
[TBL] [Abstract][Full Text] [Related]
10. Polysarcosine-based lipid formulations for intracranial delivery of mRNA.
Bi D; Unthan DM; Hu L; Bussmann J; Remaut K; Barz M; Zhang H
J Control Release; 2023 Apr; 356():1-13. PubMed ID: 36803765
[TBL] [Abstract][Full Text] [Related]
11. Time Interval of Two Injections and First-Dose Dependent of Accelerated Blood Clearance Phenomenon Induced by PEGylated Liposomal Gambogenic Acid: The Contribution of PEG-Specific IgM.
Wang F; Ye X; Wu Y; Wang H; Sheng C; Peng D; Chen W
J Pharm Sci; 2019 Jan; 108(1):641-651. PubMed ID: 30595169
[TBL] [Abstract][Full Text] [Related]
12. Effect of Repeated Injections of Adenosine Diphosphate-Encapsulated Liposomes Coated with a Fibrinogen γ-Chain Dodecapeptide Developed as a Synthetic Platelet Substitute on Accelerated Blood Clearance in a Healthy and an Anticancer Drug-Induced Thrombocytopenia Rat Model.
Taguchi K; Hashimoto M; Ogaki S; Watanabe H; Takeoka S; Ikeda Y; Handa M; Otagiri M; Maruyama T
J Pharm Sci; 2015 Sep; 104(9):3084-91. PubMed ID: 25755009
[TBL] [Abstract][Full Text] [Related]
13. A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes.
Shimizu T; Abu Lila AS; Fujita R; Awata M; Kawanishi M; Hashimoto Y; Okuhira K; Ishima Y; Ishida T
Eur J Pharm Biopharm; 2018 Jun; 127():142-149. PubMed ID: 29462689
[TBL] [Abstract][Full Text] [Related]
14. Relationship between the concentration of anti-polyethylene glycol (PEG) immunoglobulin M (IgM) and the intensity of the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes in mice.
Hashimoto Y; Shimizu T; Abu Lila AS; Ishida T; Kiwada H
Biol Pharm Bull; 2015; 38(3):417-24. PubMed ID: 25757923
[TBL] [Abstract][Full Text] [Related]
15. Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance.
Kaminskas LM; McLeod VM; Porter CJ; Boyd BJ
J Pharm Sci; 2011 Nov; 100(11):5069-77. PubMed ID: 21721002
[TBL] [Abstract][Full Text] [Related]
16. Influence of phospholipid types and animal models on the accelerated blood clearance phenomenon of PEGylated liposomes upon repeated injection.
Xu H; Ye F; Hu M; Yin P; Zhang W; Li Y; Yu X; Deng Y
Drug Deliv; 2015; 22(5):598-607. PubMed ID: 24524364
[TBL] [Abstract][Full Text] [Related]
17. Application of polyglycerol coating to plasmid DNA lipoplex for the evasion of the accelerated blood clearance phenomenon in nucleic acid delivery.
Abu Lila AS; Uehara Y; Ishida T; Kiwada H
J Pharm Sci; 2014 Feb; 103(2):557-66. PubMed ID: 24347396
[TBL] [Abstract][Full Text] [Related]
18. Anti-PEG IgM Is a Major Contributor to the Accelerated Blood Clearance of Polyethylene Glycol-Conjugated Protein.
Mima Y; Hashimoto Y; Shimizu T; Kiwada H; Ishida T
Mol Pharm; 2015 Jul; 12(7):2429-35. PubMed ID: 26070445
[TBL] [Abstract][Full Text] [Related]
19. Polysarcosine as an Alternative to PEG for Therapeutic Protein Conjugation.
Hu Y; Hou Y; Wang H; Lu H
Bioconjug Chem; 2018 Jul; 29(7):2232-2238. PubMed ID: 29863329
[TBL] [Abstract][Full Text] [Related]
20. Polysarcosine as PEG Alternative for Enhanced Camptothecin-Induced Cancer Immunogenic Cell Death.
Yao X; Sun C; Xiong F; Zhang W; Yao W; Xu Y; Fan W; Huo F
ACS Appl Mater Interfaces; 2024 Apr; 16(15):19472-19479. PubMed ID: 38572784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]